|Year : 2019 | Volume
| Issue : 1 | Page : 11-16
Thyroid-stimulating hormone in hypothyroidism – How high is too high?
Ruth Priya Senthiappan1, Smitha Bhat2, Sudeep Krishna3
1 Department of Medicine, SDM College, Dharwad, Karnataka, India
2 Departmen of Medicine, Father Muller Medical College, Mangalore, Karnataka, India
3 Departemnt of Endocrinology, Father Muller Medical College, Mangalore, Karnataka, India
|Date of Web Publication||10-Jun-2019|
Dr. Smitha Bhat
Department of Medicine, Father Muller Medical College, Mangalore, Karnataka
Source of Support: None, Conflict of Interest: None
Background: The prevalence of hypothyroidism in the developed world is about 4-5% and in India is 10.9%. The goal of treating hypothyroidism is to maintain thyrotropin (TSH) levels within the normal reference range. Studies have shown that even within the normal range of TSH, patients with low normal TSH (LNT) have better outcomes when compared to patients with high normal TSH (HNT). Aims and Objectives: Our study aimed to find whether patients treated at a dose of levothyroxine resulting in an LNT had improved clinical outcomes and biochemical parameters, when compared to those on a levothyroxine dose resulting in an HNT. Materials and Methods: 180 patients with hypothyroidism on treatment, who had a TSH of 0.27-4.2mIU/L and had been on treatment with a stable dose of at least 50 micrograms of levothyroxine for at least 6 months were administered the Thyroid Symptom Questionnaire. TSH was assayed. Blood pressure and BMI were measured. Serum lipids were measured by spectrophotometry. Results: We found that patients with LNT and HNT did not differ with respect to cognitive symptoms , feelings of coldness, lethargy and fatigue. However, patients with LNT had a better lipid profile (mean LDL 132.24 in HNT and 115.39 in LNT p= 0.08) and lower BMI (1.045kg/m 2 lower in LNT compared to HNT) compared to HNT. Conclusion: Treating patients with a dose of thyroxine titrated to achieve LNT might decrease the cardiovascular risk by improving the lipid profile and BMI.
Keywords: Hypothyroidism, optimal thyroid-stimulating hormone, symptom relief
|How to cite this article:|
Senthiappan RP, Bhat S, Krishna S. Thyroid-stimulating hormone in hypothyroidism – How high is too high?. Acta Med Int 2019;6:11-6
| Introduction|| |
Hypothyroidism is common around the world and in India. The prevalence of hypothyroidism in India is 10.9%. Yet, hypothyroidism is often underdiagnosed and undertreated. Untreated hypothyroidism is associated with dyslipidemia, obesity, poor cognitive function, and pregnancy loss. It increases the risk of coronary artery disease (CAD). The treatment of hypothyroidism with levothyroxine improves patient well-being. In addition, blood pressure (BP), body mass index (BMI), and biochemical parameters, including the lipid profile normalized.
The therapeutic endpoint for the treatment of hypothyroidism is the thyroid-stimulating hormone (TSH) level, and immunometric assays for TSH are extremely sensitive. Conventionally, 4–5 mIU/L is used as the upper normal limit of TSH. However, within the normal range of TSH itself, there is a difference in clinical outcomes and biochemical parameters. There is a difference of opinion regarding the target TSH in patients are treated for hypothyroidism, and data are lacking as to the clinical and biochemical benefit of achieving low-normal TSH (LNT) values in the treatment of hypothyroidism.
This study was an attempt to find whether patients treated at a dose of levothyroxine resulting in an LNT had improved clinical outcomes in terms of well-being, lower BMI and better biochemical parameters when compared to patients treated to a target of high normal TSH (HNT).
- To correlate TSH with lipid levels, BP, and BMI in hypothyroid patients on treatment
- To find whether patients with LNT had improved well-being when compared to patients with HNT.
| Materials and Methods|| |
The study was conducted on hypothyroid patients availing the out-patient and in-patient services of a medical college hospital in Mangalore, a city on the West coast of South India.
During the study period of 18 months, 180 consecutive adult patients with hypothyroidism on treatment, who fulfilled the inclusion criteria, were recruited for the study. Written informed consent was obtained. Patients who included in the study had a TSH of 0.27–4.2 mIU/L and had been on treatment with a stable dose of at least 50 μg of levothyroxine for at least 6 months. TSH was assayed by electro-chemiluminescence immunoassay that has a sensitivity of 0.005–100 μIU/ml. We excluded the patients who were on treatment for psychiatric illness, as also conditions which affected the lipid profile, i.e., chronic kidney disease. Patients who were already on treatment for dyslipidemia were excluded from the study.
Recruited patients were administered the Thyroid Symptom Questionnaire (TSQ). BP and BMI were measured. Serum lipids were measured by the spectrophotometry.
| Results|| |
Of the 180 participants in the study, 96.1% were female and 3.9% were male. The majority of patients (71) were in the LNT range, i.e., 0.27 mIU/L to 1.27 mIU/L. Sixteen patients had TSH levels between 1.28 mIU/L and 2.27 mIU/L, 17 patients had TSH between 2.28 mIU/L and 3.27 mIU/L, and 51 patients had HNT, i.e., between 3.28 mIU/L and 4.27 mIU/L [Figure 1].
The mean average dose of thyroxine was the highest in LNT at 86.9 μg/day [Figure 2].
Patients with HNT had higher total cholesterol and low-density lipoprotein-cholesterol (LDL-C) values but no significant difference in high-density lipoprotein (HDL) or very low-density lipoprotein values [Figure 3] and [Figure 4].
|Figure 4: Thyroid-stimulating hormone versus low-density lipoprotein cholesterol|
Click here to view
Patients in the LNT group had higher diastolic BP and higher BMI [Figure 5] and [Figure 6].
We found that patients with irregular cycles and infertility were more frequent in the HNT group, while menorrhagia was a more common complaint in the LNT group. A higher number of patients in the LNT complained of headache.
There was no difference between groups in the cognitive parameters assessed by the TSQ, i.e., clumsiness, making careless mistakes, inability to remember things, or to find the right word [Figure 7], [Figure 8], [Figure 9], [Figure 10].
|Figure 10: Thyroid Symptom Questionnaire difficulty in finding the right word|
Click here to view
| Discussion|| |
Hypothyroidism can present with multiple symptoms which impair the quality of life. Hypothyroidism is diagnosed and therapy monitored by assessing the level of TSH. Symptoms tend to correlate with TSH level with patients with higher TSH are more symptomatic. At present, the third-generation chemiluminometric assays are available, and the detection limit is 0.01. The optimal normal range of TSH remains controversial. The upper limit of TSH in most labs is considered to be 4–4.5 mIU/L. However, a large study showed that most euthyroid individuals had TSH <2.5 mIU/L. Another study showed that most euthyroid participants had a TSH ranging between 0.3 and 3.63 mIU/L. It is worth noting that TSH levels do not remain constant throughout life but tend to increase with age.
Even when treated, not all the symptoms remit, and not all patients are satisfied with the management of their disease. It is possible that this dissatisfaction is due to an inadequate dose of thyroxine replacement. It has been found that patients feel relatively healthier when they are slightly hyperthyroid. In fact, some studies have assessed whether supplementing thyroxine in patients who are clinically hypothyroid, but biochemically euthyroid has any benefit. These studies have shown conflicting results with some studies showing benefit while others do not., Thus, controversy prevails about the reference range of normal TSH.
In view of this lack of clarity regarding a target TSH level, we wanted to find whether, while treating hypothyroidism titrating to a lower range of TSH resulted in better outcomes.
We assessed well-being and cognition with the TSQ. The TSQ was designed by Saravanan et al. It uses 12 questions to assess the symptoms in patients who are being treated for hypothyroidism. It has been used to assess well-being and cognition in various studies, including ones to assess the impact of treating hypothyroidism with a combination of levothyroxine and liothyronine.
In this cross-sectional study of patients with treated hypothyroidism and normal levels of TSH, the majority of patients 71 (39%) had a LNT, and 58 (28%) patients had HNT. The remaining had TSH between 1.28 and 3.27 mIU/L. Those treated with a higher dose of thyroxine had an LNT. They were found to have lower LDL-C, higher diastolic BP, and an increased incidence of headache. Patients treated to an HNT had a higher chance of being infertile or having irregular menstrual cycles.
This study contrasts with work done by a Reh et al. which did not find a higher rate of infertility or miscarriage in patients treated to an HNT. Even within the normal range, our patients with a higher TSH tended to have a higher body weight. Thyroid function variation even within the normal range might be one of the factors determining the body weight, with a significant association found with a BMI >30 and serum TSH levels.
Hypothyroidism results in cognitive and emotional dysfunction. The depression and fatigue are both due to the thyroid disease itself and the effect of thyroxine deficiency on the brain tissue. When hypothyroidism is treated, the recovery of emotional and cognitive dysfunction is inconsistent. We found no significant benefit in terms of less tiredness or improved cognitive function in patients treated to an LNT. Previous studies have also shown that psychological well-being is not one of the parameters which improve with the treatment of hypothyroidism. This is in contrast to studies which show that treating autoimmune hypothyroidism and subclinical hypothyroidism results in some improvement in fatigue. Interestingly, it has been found that amelioration of fatigue when hypothyroidism is treated does not depend on the absolute value of TSH so much as the fall in TSH values with treatment. Another factor which might have influenced persistence of fatigue even after the treatment is the fact that the majority of our patients were female, and females were more likely to complain of persistent fatigue even after the treatment.
Participants with LNT had lower total and LDL-C levels. Even within the normal range of TSH, increasing TSH correlates with increasing LDL-C and decreasing HDL cholesterol levels. Thyroxine induces HMG co-A-reductase, and T3 upregulates LDL receptors. In addition, thyroid hormones increase the activity of cholesteryl ester transfer protein. Hypothyroidism is associated with dyslipidemia, hypertension, and elevated levels of homocysteine. In addition, endothelial dysfunction has been noted in hypothyroidism. Thus, the implication of hypothyroidism in CAD is multifactorial. Subclinical hypothyroidism has also been shown to increase the risk of coronary heart disease. Whether treating patients with mild hypothyroidism decreased the incidence of CAD has been studied. It was found that though treating hypothyroidism improved the lipid profile, this did not translate into an overall mortality benefit.
Patients with LNT did not fare better in terms of well-being and quality of life.
The literature shows that various symptoms of hypothyroidism respond differently to treatment with levothyroxine and not all are ameliorated even with normal TSH.
In this study, infertility and menorrhagia were more common with HNT. We found that patients with HNT had a higher rate of infertility and irregular menstrual cycles. Subclinical hypothyroidism impacts reproductive health and results in increased risks of abruptio placentae and preterm delivery.
In patients being treated for hypothyroidism, inadequate replacement with levothyroxine results in abortion and premature delivery. Normal TSH levels seem to be a prerequisite for normal conception and delivery, as even HNT may result in infertility.
It has been found that even subclinical or minimal hypothyroidism during pregnancy is associated with a greater risk of miscarriage, and may also have far-reaching adverse consequences on later cognitive development of the infant. Therefore, patients with menstrual disturbances and expectant mothers might benefit from titration to LNT.
There were some interesting findings which could not be explained by chance alone. We found that headache was one of the symptoms that worsened when hypothyroidism was treated to LNT. This has been seen in other studies, including a large cross-sectional study where the prevalence of headache was greater in individuals with an LNT. It was speculated that LNT reflected high adrenergic activity. The role of the sympathetic nervous system in the pathogenesis of migraine has been suggested by various researchers.,
In a large population-based study in Norway, it was found that women with higher TSH values had a lower headache prevalence. However, hypothyroidism is itself known to cause headaches and must be ruled out while treating headache. The influence of thyroxine on headache is not clear yet and requires further work.
Another interesting finding was the increased diastolic blood pressure in patients with LNT. One study showed that, within the normal range of TSH, different levels of TSH had no relation with the BP. However, there is contradictory evidence regarding the effect of TSH within the normal range on BP – a study on the elderly Chinese women showed that HNT was an independent risk factor for the development of hypertension. Whether the effect of the thyroid on BP is influenced by ethnicity is a question that remains to be answered.
This study had certain limitations. First, the TSQ was initially not developed for the use of Indian patients, and the responses when translated into the local language may have reflected symptoms and the state of well-being less accurately. It depends on responses by the patient and hence suffers from the inherent limitation of a subjective instrument. The study was not blinded.
| Conclusion|| |
In spite of these limitations, an important take-home message from this study is that treating hypothyroid patients with a dose of thyroxine titrated to maintain LNT resulted in lower BMI and lower total and LDL-C. This might decrease cardiovascular risk. Randomized controlled trials with more objective measures of well-being will help to elucidate ideal target levels of TSH.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004;363:793-803.
LeGrys VA, Hartmann K, Walsh JF. The clinical consequences and diagnosis of hypothyroidism. Clin Lab Sci 2004;17:203-8.
Laclaustra M, Hurtado-Roca Y, Sendin M, Leon M, Ledesma M, Andres E. Lower-normal TSH is associated with better metabolic risk factors: A cross-sectional study on Spanish men. Nutr Metab Cardiovasc Dis 2015;25:1095-103.
Laurberg P, Andersen S, Carlé A, Karmisholt J, Knudsen N, Pedersen IB, et al.
The TSH upper reference limit: Where are we at? Nat Rev Endocrinol 2011;7:232-9.
Jaeschke R, Guyatt G, Cook D, Harper S, Gerstein HC. Spectrum of quality of life impairment in hypothyroidism. Qual Life Res 1994;3:323-7.
Canaris GJ, Steiner JF, Ridgway EC. Do traditional symptoms of hypothyroidism correlate with biochemical disease? J Gen Intern Med 1997;12:544-50.
Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al.
Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf) 2003;58:138-40. Available fom: http://www.ncbi.nlm.nih.gov/pubmed/12625976
. [Last accessed on 2017 Mar 13]
Kratzsch J, Fiedler GM, Leichtle A, Brügel M, Buchbinder S, Otto L, et al.
New reference intervals for thyrotropin and thyroid hormones based on national academy of clinical biochemistry criteria and regular ultrasonography of the thyroid. Clin Chem 2005;51:1480-6.
Bremner AP, Feddema P, Leedman PJ, Brown SJ, Beilby JP, Lim EM, et al.
Age-related changes in thyroid function: A longitudinal study of a community-based cohort. J Clin Endocrinol Metab 2012;97:1554-62.
Walsh JP. Dissatisfaction with thyroxine therapy – Could the patients be right? Curr Opin Pharmacol 2002;2:717-22.
Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: Comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf) 1988;28:325-33.
Pollock MA, Sturrock A, Marshall K, Davidson KM, Kelly CJ, McMahon AD, et al.
Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: Randomised double blind placebo controlled crossover trial. BMJ 2001;323:891-5.
Skinner GR, Holmes D, Ahmad A, Davies JA, Benitez J. Clinical response to thyroxine sodium in clinically hypothyroid but biochemically euthyroid patients. J Nutr Environ Med 2009;10:115-24.
Hagen K, Bjøro T, Zwart JA, Vatten L, Stovner LJ, Bovim G. Low headache prevalence amongst women with high TSH values. Eur J Neurol 2001;8:693-9.
Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of l-thyroxine: Results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf) 2002;57:577-85.
Reh A, Grifo J, Danoff A. What is a normal thyroid-stimulating hormone (TSH) level? Effects of stricter TSH thresholds on pregnancy outcomes after in vitro
fertilization. Fertil Steril 2010;94:2920-2.
Knudsen N, Laurberg P, Rasmussen LB, Bülow I, Perrild H, Ovesen L, et al.
Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005;90:4019-24.
Davis JD, Tremont G. Neuropsychiatric aspects of hypothyroidism and treatment reversibility. Minerva Endocrinol 2007;32:49-65.
Winther KH, Cramon P, Watt T, Bjorner JB, Ekholm O, Feldt-Rasmussen U, et al.
Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy. PLoS One 2016;11:e0156925.
Rugge JB, Bougatsos C, Chou R. Screening and treatment of thyroid dysfunction: An evidence review for the U.S. Preventive services task force. Ann Intern Med 2015;162:35-45.
El-Haddad B, Bizri IE, Kallail KJ, Zackula RE, Hoffman JM. Fatigue and TSH levels in hypothyroid patients. Kansas J Med 2012;5:51-7.
Asvold BO, Vatten LJ, Nilsen TI, Bjøro T. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT study. Eur J Endocrinol 2007;156:181-6.
Bakker O, Hudig F, Meijssen S, Wiersinga WM. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun 1998;249:517-21.
McQuade C, Skugor M, Brennan DM, Hoar B, Stevenson C, Hoogwerf BJ, et al.
Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: A PreCIS database study. Thyroid 2011;21:837-43.
Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, et al.
Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: Beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab 2003;88:3731-7.
Rodondi N, Aujesky D, Vittinghoff E, Cornuz J, Bauer DC. Subclinical hypothyroidism and the risk of coronary heart disease: A meta-analysis. Am J Med 2006;119:541-51.
Danese MD, Ladenson PW, Meinert CL, Powe NR. Clinical review 115: Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: A quantitative review of the literature. J Clin Endocrinol Metab 2000;85:2993-3001.
Flynn RW, Macdonald TM, Jung RT, Morris AD, Leese GP. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 2006;91:2159-64.
Casey BM, Dashe JS, Wells CE, McIntire DD, Byrd W, Leveno KJ, et al.
Subclinical hypothyroidism and pregnancy outcomes. Obstet Gynecol 2005;105:239-45.
Abalovich M, Gutierrez S, Alcaraz G, Maccallini G, Garcia A, Levalle O, et al.
Overt and subclinical hypothyroidism complicating pregnancy. Thyroid 2002;12:63-8.
Verma I, Sood R, Juneja S, Kaur S. Prevalence of hypothyroidism in infertile women and evaluation of response of treatment for hypothyroidism on infertility. Int J Appl Basic Med Res 2012;2:17-9.
Sarkar D. Recurrent pregnancy loss in patients with thyroid dysfunction. Indian J Endocrinol Metab 2012;16:S350-1.
Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: Proof of efficacy, utilization and cost. Cephalalgia 1997;17:73-80.
Hassinger HJ, Semenchuk EM, O'Brien WH. Cardiovascular responses to pain and stress in migraine. Headache 1999;39:605-15.
Stronks DL, Tulen JH, Verheij R, Boomsma F, Fekkes D, Pepplinkhuizen L, et al.
Serotonergic, catecholaminergic, and cardiovascular reactions to mental stress in female migraine patients. A controlled study. Headache 1998;38:270-80.
Tepper DE, Tepper SJ, Sheftell FD, Bigal ME. Headache attributed to hypothyroidism. Curr Pain Headache Rep 2007;11:304-9.
Liu D, Jiang F, Shan Z, Wang B, Wang J, Lai Y, et al.
A cross-sectional survey of relationship between serum TSH level and blood pressure. J Hum Hypertens 2010;24:134-8.
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7], [Figure 8], [Figure 9], [Figure 10]